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Prolonged IgM Antibody Response in People Infected with Zika Virus: 





In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with 
Possible Zika Virus Exposure – United States, July 2016 
(https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) that includes Zika virus immunoglobulin M 
(IgM) testing of pregnant women. However, some flavivirus infections can result in prolonged IgM 
responses (>12 weeks) that make it difficult to determine the timing of infection, especially in testing of 
asymptomatic people. Emerging epidemiologic and laboratory data indicate that Zika virus IgM can 
persist beyond 12 weeks in a subset of infected people. Therefore, detection of IgM may not always 
indicate a recent infection. Although IgM persistence could affect IgM test interpretation for all infected 
people, it would have the greatest effect on clinical management of pregnant women with a history of 
living in or traveling to areas with Zika virus transmission before conception. Pregnant women who test 
positive for IgM antibody may have been infected with Zika virus and developed an IgM response before 
conception.  
 
For asymptomatic pregnant women living in or frequently traveling to areas with Zika virus transmission, 
Zika virus nucleic acid test (NAT) testing at least once per trimester should be considered, in addition to 
IgM testing as previously recommended. If positive, this may provide a more definitive diagnosis of recent 
Zika infection. However, a negative NAT does not rule out recent infection because viral ribonucleic acid 
(RNA) declines over time. Other diagnostic methods, such as NAT testing of amniocentesis specimens or 
serial ultrasounds, may provide additional information to help determine whether the IgM test results 
suggest a recent infection. Providers should counsel women on the limitations of all tests. In addition, 
providers may wish to consider IgM testing as part of pre-conception counseling to establish baseline IgM 
results before pregnancy; however, preconception negative IgM results might have limited value for 
women at ongoing risk of Zika infection. NAT testing should be performed for any pregnant woman who 
becomes symptomatic or who has a sexual partner who tests positive for Zika virus infection.  
 
Recommendations 
For asymptomatic pregnant women living in or frequently traveling to areas with Zika virus transmission 
with posted CDC Zika Travel Notices (https://wwwnc.cdc.gov/travel/page/zika-information), CDC 
recommends that healthcare providers take these steps: 
1) Screen pregnant women for risk of Zika exposure and symptoms of Zika. Promptly test pregnant 
women with NAT if they become symptomatic during their pregnancy or if a sexual partner tests 
positive for Zika virus infection. 
2) Consider NAT testing at least once per trimester, unless a previous test has been positive.* 
3) Consider NAT testing of amniocentesis specimens if amniocentesis is performed for other 
reasons.† 
4) Counsel pregnant women each trimester on the limitations of IgM and NAT testing. For more 
information about Zika virus testing, see: https://www.cdc.gov/zika/pdfs/living_in.pdf. For more 
information about counseling before testing, see: 
https://www.cdc.gov/zika/pdfs/pretestingcounselingscript_livingin.pdf.  
5) Consider IgM testing to determine baseline Zika virus IgM levels as part of preconception 
counseling.§ For more information about preconception counseling, see:  
https://www.cdc.gov/zika/pdfs/preconception-counseling.pdf 
 
Recommendations for testing symptomatic pregnant women, remain unchanged 
(https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm). However, if a symptomatic pregnant woman 
is IgM positive and NAT negative, and lived in or traveled to an area with a posted CDC Zika Travel 
Notice (https://wwwnc.cdc.gov/travel/page/zika-information), healthcare providers should recognize that 
the positive IgM result does not necessarily indicate recent infection. 
 
CDC will update clinical management (https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) and 
laboratory testing (https://www.cdc.gov/zika/laboratories/lab-guidance.html) recommendations as new 
information becomes available. 
 
Background 
Some flavivirus infections have been reported to result in prolonged IgM responses that make it difficult to 
differentiate recent from prior infections in areas with ongoing transmission. For dengue virus, IgM was 
determined to persist for 6 months (179 days [95% confidence interval, 155 to 215 days]) for primary 
infections and 4.6 months (139 days [95% confidence interval, 119 to 167 days]) after infection with 
another flavivirus1. IgM antibodies against West Nile virus, another flavivirus related to Zika virus, have 
been detected in asymptomatic, infected blood donors for at least three months after they donated blood, 
and almost half of tested patients with West Nile virus infection had serum IgM antibodies >1 year after 
infection2,3.  
 
Recent findings suggest that Zika virus infection may also result in IgM persistence that may make it 
difficult to differentiate prior from recent infections. A recent study in Puerto Rico of symptomatic patients 
with NAT-confirmed Zika virus infection detected Zika virus IgM in 100% (28/28) of participants at 8 to 15 
days after symptom onset, and 87% (52/60) at greater than 60 days after symptom onset4. Unpublished 
data on the symptomatic patients from this ongoing study show a median time to first negative Zika virus 
IgM as 4 months (122 days [range 8-210 days]). More data are needed to accurately estimate the 
proportion of persons who are likely to have Zika IgM persist beyond 12 weeks after infection. 
 
IgM test results can also be difficult to interpret because of cross-reactivity with other flaviviruses, 
particularly dengue virus, when a person has been previously infected or vaccinated with a related 
flavivirus. During 2016, Puerto Rico had limited dengue virus transmission and, therefore, people who 
tested positive for Zika IgM antibody could be assumed to have had recent Zika virus infection. However, 
if dengue virus transmission were to increase, guidance for interpretation of Zika virus IgM testing results 
may need to be reconsidered. 
 
NAT testing may be useful in testing pregnant women as an indicator of current infection and increased 
risk to the fetus. In the same study from Puerto Rico discussed above, viral RNA was detected in 36% 
(10/28) of participants at 8‒15 days after symptom onset, 21% (27/129) at 16‒30 days after symptom 
onset, and 4% (3/79) more than 60 days after symptom onset4. A limited number of studies have 
demonstrated detection of viral nucleic acid in some pregnant women for even longer periods after 
symptom onset. For example, three of the five pregnant women included in the study from Puerto Rico 
had detectable RNA at 46 days and one still had detectable RNA at 80 days after symptom onset4. In 
another case series, some pregnant women had Zika virus RNA detectable up to 107 days after symptom 
onset5.   
 
For More Information 
Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus 
Exposure - United States, July 2016. MMWR Morb Mortal Wkly Rep. 2016 Jul 25;65(29):739-44. 
https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm  
 
Guidance for U.S. Laboratories Testing for Zika Virus Infection. https://www.cdc.gov/zika/laboratories/lab-
guidance.html 
 
Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika 
Virus for Persons with Possible Zika Virus Exposure - United States, September 2016. MMWR Morb 
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* Birth defects have been reported in a higher proportion of fetuses or infants whose mothers were 
infected during the first trimester of pregnancy than in later trimesters. In pregnancies with symptom onset 
or exposure during the first trimester that were limited to those with laboratory-confirmed Zika virus 
infection, 15% of completed pregnancies had reported birth defects of the type seen with congenital Zika 
infection6. 
† Consideration of amniocentesis should be individualized, because data about its usefulness in 
diagnosing congenital Zika virus infection are limited. The presence of Zika virus RNA in the amniotic fluid 
might indicate fetal infection; however, a negative result does not exclude congenital Zika virus infection  
§ Preconceptional IgM testing is recommended to establish a baseline IgM level before pregnancy.  
However, given the limitations of interpreting IgM testing, the results of these tests should not be used to 
guide decisions about pregnancy timing for women living in areas with ongoing risk of transmission.  
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